MidCycle Meeting Agenda

Sponsor: **ClinImmune**
BLA #: **BLA 124391**
Product: **Hematopoietic stem/progenitor cells, cord (HPC-C)**

1. Review Team

Discipline	Name	Phone
Product Reviewer/Chair	Yong Fan	301 827 6038
	Lilia Bi	301 827 4016
	Safa Karandish	301 827 2477
Pharm/Tox Reviewer	Atm S. Hoque	301 827 9071
Clinical Reviewer	Rachel Witten	301 827 9134
RPM	Ramani Sista	301 827 5152
Labeling Reviewer	Loan Nguyen/Lisa Stockbridge	301 827 6333
DMPQ Reviewer	Mohammad Heidaran/Marion Michaelis	301 827 7186
BIMO Reviewer	Dennis Cato	301 827 2588
Statistics Reviewer	Chunrong Cheng	301 827 6053

Meeting attendees: Haudenschild, Changting; Wonnacott, Keith; Bryan, Wilson; Norwood, Laurie; Simek, Stephanie; Benton, Kimberly; Riggins, Patrick; Fan, Yong; Cheng, Chunrong; Cato, Dennis; Heidaran, Mohammad; Witten, Celia (CBER); Karandish, Safa; Witten, Rachel; Bi, Lilia Lei; Nguyen, Loan; Abbasi, Fatima; Lee, Shiowjen; Zhu, Yao-Yao; Sista, Ramani

2. Official Milestones and Monthly Goals

The current due date is **March 2, 2012**. **(10 month clock)**

~~*Filing Meeting*: June 21, 2011~~
~~*Filing Letter Action/Comments:* COB, Friday, June 24, 2011~~
~~*60 day: July 3, 2011*~~
~~*74 day/Filing Letter: Friday, July 15,* 2011~~
Mid-cycle Review Meeting: October 6, 2011 – **DRAFT Reviews Due to Celia**
Team Meetings: ~~August 10~~ and November 16, 2011
Wrap up Meeting: January 5, 2012

3. Outstanding issues

Manufacture (YF)

(1). Collection validation is deficient, the applicant will resubmit the collection validation.

(2). The -------(b)(4)------- used during collection is not a 510(k) cleared device. The reviewer requested information regarding raw material, manufacture and biocompatibility.
(3). The manual processing method validation is deficient, the applicant needs to submit an acceptable validation report.
(4). The -----(b)(4)----- freezer validation is deficient, the applicant agreed to re-validate it once the assay validations described by Dr. Bi are completed.
(5). The stability study used products manufactured using the ---(b)(4)--- processing method only, and the majority of the units intended to license are manufactured using the -------(b)(4)------- method. The comparison of these two processing methods doesn't demonstrate comparability, the applicant needs to submit an acceptable comparability report.

Release Testing (LB, FA and JG):

(1). The cell count validation is deficient, the applicant agreed to revalidate the assay and submit the validation report upon completion (LB).
(2). The ---(b)(4)--- viability assay validation and SOP are deficient, the applicant will validate the assay and submit the revised SOP upon completion (LB).
(3). Sterility test validation is deficient(JG).
(4). The growth-promotion test is deficient(JG).
(5). The study also does not include a test to determine the suitability of the method i.e. the verification of the Bacteriostatic/Fungistatic effect of the ------(b)(4)-------(JG).
(6). The sponsor is using a --(b)(4)-- incubation period for their sterility test instead of the USP <71> and 21 CFR § 610.12 recommended 14 days. No supporting data were provided to justify this reduction in incubation time (JG).

Donor Eligibility(SK):

(1). Donor eligibility SOPs lack sufficient details regarding the risk factors assessed during the review of medical records, assessment of birth mothers for plasma dilution, documentation of donor eligibility determination and identification of donor eligibility in the search inventory.
(2). Clarification is needed regarding the donor screening process at non-fixed collection sites.

Clinical (RW)

(1). Awaiting revised outcomes dataset
(2). Awaiting consent forms and clinical protocols for every collection site.

DMPQ (MM and MH)

1. Plan to propose the physical and electronic sections of IND and licensed units.

2. Retention sample, discussion with OCTGT at later time point.
3. Inspectional issues discussed with Sponsor, information provided or commitment to provide information in timely fashion.

4. Review format – attach word file to concurred pdf review.

5. Next Steps

A. Team Meeting – November 16

B. *Send another letter to ClinImmune to convey the outstanding issues related to DE and Sterility validation and testing (Other deficiencies have been conveyed to ClinImmune through T0con).*